Fenofibrate: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
Line 1: Line 1:
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='97/977745/Cv/1'>
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='97/977745/Cv/1'>
Fenofibrate (sold under the brand names Tricor, Fenobrat etc.), is an oral medication of the fibrate class used to treat abnormal blood lipid levels.<ref name="a2">"Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.</ref> It is less commonly used compared than statins because it treats a different type of cholesterol abnormality to statins. While statins have strong evidence for reducing heart disease and death, there is evidence to suggest that fenofibrate also reduces to the risk of heart disease and death. However, this seems only to apply to specific populations of people with elevated triglyceride levels and reduced high-density lipoprotein (HDL) cholesterol.<ref name="a2">"Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.</ref><ref name="a3">PMID:20228404</ref><ref name="a4">PMID:31562117</ref> See also [https://en.wikipedia.org/wiki/Fenofibrate].
Fenofibrate (sold under the brand names Tricor, Fenobrat etc.), is an oral medication of the fibrate class used to treat abnormal blood lipid levels.<ref name="a2">"Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.</ref> It is less commonly used compared than statins because it treats a different type of cholesterol abnormality to statins. While statins have strong evidence for reducing heart disease and death, there is evidence to suggest that fenofibrate also reduces to the risk of heart disease and death. However, this seems only to apply to specific populations of people with elevated triglyceride levels and reduced high-density lipoprotein (HDL) cholesterol.<ref name="a2">"Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.</ref><ref name="a3">PMID:20228404</ref><ref name="a4">PMID:31562117</ref> See also [https://en.wikipedia.org/wiki/Fenofibrate].
In summary, enhanced catabolism of triglyceride-rich particles and reduced secretion of VLDL underlie the hypotriglyceridemic effect of fibrates, whereas their effect on HDL metabolism is associated with changes in HDL apolipoprotein expression.<ref name="a28">PMID:9808609</ref>
Fenofibrate is a fibrate derivative, a prodrug comprising fenofibric acid linked to an isopropyl ester. It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα). PPARα activates lipoprotein lipase and reduces apoprotein CIII, which increases lipolysis and elimination of triglyceride-rich particles from plasma.<ref name="a28">PMID:9808609</ref>
PPARα also increases apoproteins AI and AII, reduces VLDL- and LDL-containing apoprotein B, and increases HDL-containing apoprotein AI and AII.


<scene name='97/977745/Cv/2'>PPARalpha ligand binding domain-fenofibric acid co-crystals</scene> ([[6lx4]]).
<scene name='97/977745/Cv/2'>PPARalpha ligand binding domain-fenofibric acid co-crystals</scene> ([[6lx4]]).

Revision as of 12:10, 20 July 2023

Caption for this structure

Drag the structure with the mouse to rotate

References

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky, Michal Harel